A pilot metabolomic study of drug interaction with the immune response to seasonal influenza vaccination.

Authors:
Siddiqa A; Wang Y; Thapa M; Martin DE; Cadar AN and 2 more

Journal:
NPJ Vaccines

Publication Year: 2023

DOI:
10.1038/s41541-023-00682-2

PMCID:
PMC10261085

PMID:
37308481

Journal Information

Full Title: NPJ Vaccines

Abbreviation: NPJ Vaccines

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
5/6
83.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"data availability the metabolomics data have been submitted to metabolomics workbench and publicly available under study id st002432"

Code Sharing
Evidence found in paper:

"Competing interests The authors declare no competing interests."

Evidence found in paper:

"This research was conducted while JMB was Diamond/American Federation for Aging Research (AFAR) award recipient. This work was in parted funded by NIH grants NCI U01 CA235493 (SL), NIAID R01 AI149746 (SL), NIA P30AG067988 (SL and JMB, the UConn Claude D. Pepper Older Americans Independence Center). ANC was supported by a NIAMS/NIH predoctoral fellowship (T32AR079114). We thank Drs Haoxin Li, Marios Giannakis and Kevin Bullock for providing metabolite identification information in the Broad dataset."

Evidence found in paper:

"All participants were vaccinated with Fluzone high-dose trivalent flu vaccine (Sanofi Pasteur Inc., Swiftwater, PA) after ~70 days of treatment. Blood was drawn via standard venipuncture into EDTA-treated vacutainers prior to treatment (Day 0), prior to vaccination (~day 35 and ~day 70), and 7, ~35, and ~70 days post vaccination. The study protocol was approved by the Institutional Review Board at the University of Connecticut Health Center (UCHC) and registered at ClinicalTrials.gov (NCT03996538). All study participants provided written informed consent to participate in the study."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025